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A renewed focus has been given to the 3-year-old regulation 21
CFR Part 11, Electronic Records and Electronic Signatures. This
paper gives a chronology of the process of an equipment vendor,
Zymark Corporation, validating laboratory automation equipment
for compliance to the regulation 21 CFR Part 11. Zymark’s
Tablet Processing Workstation II
TM (TPW
TM) and Prelu-
de
TM are the instruments chronicled. The ¢rst instrument, the
TPW
TM, was developed before Zymark de¢ned its strategy on
how to meet its customer’s need for 21 CFR Part 11 compliant
equipment. The TPW
TM has been available for several years,
and in the summer of 1999 it received a major software upgrade to
improve its security. The second instrument, the Prelude
TM, is a
new product. It had a design requirement to meet the regulation.
Zymark’s Part 11 strategy was already in place and used for this
development project. This chronology will include all aspects of the
exercise, including familiarization with the standard, development
of the protocols, review of the protocols by industry experts, review
of the protocols by pharmaceutical users, execution of the tests,
preparation of the exception reports, and the release of any
necessary product revisions.
Introduction
This is the story of the process that Zymark’ s Manager of
Product Testing and Validation, Stephen M. Dobro,
used to research regulation 21 CFR Part 11 and evaluate
two of Zymark’ s products for compliance with it. The
exercise created the process that Zymark now uses to
ensure compliance for all its products whose use fall
under the requirements of 21 CFR Part 11. Throughout
this document, the term ` the regulation’ and ` Part 11’
will be used interchangeably with 21 CFR Part 11.
The information is presented in chronological order. The
major topics include the following.
. Motivation and goals: why Zymark got involved
with this project and what it intended to accom-
plish.
. Understanding the regulation: what knowledge was
necessary to complete the project successfully.
. Developing the validation plan: the author’ s experi-
ence developing a protocolÐ how he went about it
and what questions came up.
. Expert and customer review: the author indicates
what others thought about his drafts of the protocol
and how those comments shaped the plan.
. Execution and results: the author shows how the
actual testing went.
Motivation and goals
What is Zymark’ s motivation for compliance with the
regulation? Zymark provides automation equipment for
use in research and analytical laboratories. Its customers
need to comply with the regulation and it is in Zymark’ s
best interest to do all that it can to meet customers’ needs.
In recent years, Zymark has been changing from an
engineering- to a market-driven company. Engineering-
driven means that the engineering department comes up
with new product ideas. Market-driven means that one
listens to customers for new product ideas as well as ideas
for quality improvements. The quality department has
been making changes to help Zymark adapt to this new
philosophy. To be a successful market-driven company,
one needs to open up and learn to listen to customers.
During 1999, the quality department spent a lot of time
talking with customers to ® nd out where to target
improvements.
Software issues were one of the major themes re¯ ected in
these customer surveys. Upon joining the quality de-
partment in January 1999, the author’ s ® rst assignment
was to evaluate Zymark’ s process for software quality
assurance. Software is the author’ s specialty, having
spent more than 10 years as a software developer. Soft-
ware quality was a topic that was coming up quite
frequently with customers. Not only was software quality
an issue, the author heard about 21 CFR Part 11 from
every customer who either came in for an audit or sent an
audit questionnaire to Zymark. The bottom line was that
Zymark’ s customers needed to comply with the regula-
tion. The project was added to the author’ s list of
projects.
Very speci® c goals were set up for the project. The ® rst
goal was to create a standard validation plan that could
be used to evaluate existing products as well as new
products. It had to be generic enough so that it could
easily be adapted for any Zymark product. A second goal
was to create a resulting package that would be of value
to Zymark’ s customers. It would not be good enough just
to meet the letter of the regulation for it was important to
satisfy customers’ needs on this topic. After all, it is
customers that have to answer to the FDA. Zymark
wanted to improve their products and wanted their
customers to believe that the testing done was good
testing. The goal was to make it good enough so that
Zymark’ s customers would like to have their own copy to
reference in their documentation.
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183Understanding the regulation
Probably the largest task associated with the project was
to understand the regulation. There were several infor-
mation sources used, which included government regula-
tions, FDA guidance documents, magazine articles,
individual experience, and, most importantly, the
author’ s previous work experience was in non-regulated
industries, so he was about to get a real learning
experience. The regulation, which he printed from the
FDA web page, was a thick document, but the regulation
itself was only the last few pages. The task, however, was
still a lengthy process.
From there, the author reviewed guidance documents,
magazine articles, information from industry consultants,
and anything else on the subject. He also reviewed
information that had been given to Zymark from custo-
mers. Some customers had already put together their
own set of guidelines, and these were bene® cial. Being
new to the industry, the author also needed to learn
about computer system validation and how it related to
21 CFR Part 211, Current Good Manufacturing Practice
for Finished Pharmaceuticals. He spoke to people at
Zymark who were familiar with pharmaceutical valida-
tions, including the ® eld service engineers who perform
Installation Quali® cation and Operational Quali® cation
when Zymark equipment is installed. Zymark also has
chemists who perform methods transfers from manual
execution to automated equipment. This education was
essential to understanding how Part 11 ® tted into the
scheme of these regulations.
As the author was gathering information, he started to
make a list of questions. One category of questions
involved ® nding diå erent interpretations of the regula-
tion from the various information sources. An example of
this is the level of security necessary: how secure does the
system have to be? Data ® les on a personal computer are
diæ cult to protect. Zymark’ s design put the audit log and
data records in a SQL Server database, which provides
for tight security. But how secure do other system ® les
need to be? Some questions did not have simple, straight-
forward answers. A second example involved unattended
terminals. If someone logs into a system and then leaves
the terminal unattended, what should happen if a diå er-
ent operator steps up to the terminal? The author later
came across an FDA guideline that helped him make a
decision on this point. As it turns out, solutions can be
implemented in many diå erent ways. A third example is
system con® guration. For Zymark products, the admin-
istrator can con® gure what operations will be password-
protected. This means that the system can be con® gured
to have very tight or minimal security. On this topic, one
of Zymark’ s customers stated that if it was possible for the
system to be con® gured not to comply with the regula-
tion, then it is a non-compliant system. These diå erences
in interpretation were part of the struggle in coming to
terms with the regulation. A second category of questions
centred on terminology. There were many phrases in the
regulation that were unclear. Some examples are: ` What
is meant by an ` ` accurate copy’ ’ of records?’ and ` What is
a ` ` device check’ ’ ?’ Gathering information was more than
just a project phase; it was a continuous process of
learning. For the author, that was about 18 months of
education so far!
Developing the validation plan
Although the author still had many unanswered ques-
tions, he began to develop the validation plan. This was a
two-step process. The ® rst step was to create a validation
plan that listed generic test cases that could be used for
any product. The author made this list of test cases
generic even though he knew which product he would
be testing ® rst. He wanted to be sure he came up with a
list of test cases that could be used for any product. When
he ® nished the generic validation plan, he had a template
that could be used for step two. The second step was to
use this template to create a speci® c validation plan for
the actual product to be tested. Each step is described in
more detail below.
When creating the generic validation plan, the author
had to answer some questions on the scope of the plan. It
was decided the generic plan should cover all Zymark
products. Next, did the plan need to address electronic
records, electronic signatures or both? This could vary
depending on the product. At ® rst, the author thought
that only the electronic records portion would apply to
Zymark products. As he learned more, it became clear
that electronic signatures also needed to be addressed.
Zymark used diå erent levels of security. Those with
proper access could change parameters, run methods or
administer the system. The next question that had to be
answered was whether the scope should include open
systems or just closed systems. All current products and
plans were for products that were closed systems. After
answering these questions, it was time to de® ne generic
test cases that would address all of the speci® c product
requirements related to the regulation.
Before the author de® ned the test cases, it was necessary
to create a requirements traceability matrix. A require-
ments traceability matrix is a table where the ® rst
column lists all of the requirements and the second
column lists one or more test cases for each requirement.
Using this matrix, one can be sure they provide at least
one test for each requirement. First, the author listed in
the table all the requirements from the regulation for
closed systems and for signature security. He took these
verbatim from the regulation. Then he carefully thought
out generic tests that would prove meeting the require-
ment and listed these in the second column. For example,
11.10c reads ` Protection of records to enable their accu-
rate and ready retrieval throughout the records retention
period’ . Dobro de® ned two generic tests: (1) new data
records must not overwrite old data records and (2)
unauthorized users must not be able to modify or remove
data records. When the matrix was complete, so was the
generic test plan. It was now time to adapt the plan for
the speci® c product.
The ® rst product to test was the Tablet Processing
Workstation II
TM (TPW
TM). The TPW
TM was chosen
® rst mainly for two reasons. First, it was an existing or
legacy product developed before the existence of the
regulation whose primary focus was for use in Pharma-
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plans to make it compliant. Second, it had been given a
recent software upgrade that incorporated a brand-new
security module.
Months later, the author adapted the plan to apply to the
Prelude
TM, a brand-new product. This was the ® rst
product that listed the regulation as a product require-
ment. Details of the Prelude
TM case follow the TPW
TM
case.
To document and test a product properly, it helps to
understand its functionality and data architecture. The
primary applications of the TPW
TM are sample prepara-
tion for assay, content uniformity, and stability testing.
The Unit performs basic functions such as table disper-
sing, dilution and ® ltration of samples. It can then feed
the sample into a measuring device such as an HPLC or
UV, or it can store the sample using a sample collection
product called EasyFill
TM.
Figure 1 shows the TPW
TM Robotic Unit. The hardware
includes test tube racks, robotic arm, ® lter dispenser,
disperser station, which contains a three-place balance,
and a dispense station, which contains a four-place
balance.
To give an understanding of how the TPW
TM handles
data, see ® gure 2. There are three boxes in the data
architecture diagram: the PC, the Robotic Unit and the
output device. The blocks within the PC show data.
Methods and solvent density are saved in individual
® les. Data records are produced and stored locally in a
SQL Server
TM Database and Excel spreadsheet. Copies
of the data can also be sent to another database or
spreadsheet using the Advanced Data Channel option
that will be discussed later. Audit trail information is
stored locally in the SQL Server
TM Database.
With general product knowledge, the speci® c test cases
for a product can be put together. The author was faced
with more questions. ` Can the plan just reference design
level testing?’ When the TPW
TM was developed, a lot of
testing, called design-level testing, was performed. The
author had this idea that he could just reference those test
results in this plan. It did not take long to realize that this
was not a good idea. It would make it diæ cult to audit
the testing and to reuse the results. Also, the testing done
for legacy products like the TPW
TM was bound to be
incomplete. It was decided that this test plan should
stand on its own.
` Does this test plan need to cover every type of operation
that the system can perform?’ For the TPW
TM, just
about every operation caused data to be recorded.
Instead of making sure that every operation was tested
(a duplication of the design level testing done at the time
of development), it was decided that the testing would
include a typical set of operations.
` What are the instrument boundaries?’ During the crea-
tion of the generic test cases, a line had to be drawn
between the TPW
TM and external equipmentÐ this was
de® ned as the instrument boundary. Two examples are
now discussed.
The ® rst example is advanced data channels, which is an
available option for the system. Advanced data channels
allow the user to store data outside of the TPW
TM’ s
secure databaseÐ perhaps even on a system network. It
was decided that this is only a copy of the secure record
and, therefore, is not within the instrument boundary.
The second example is data from detection devices
such as an HPLC or UV. Were the data from these
devices part of the system? The answer to this was no,
since the data from these devices were not returned
to the TPW
TM. Once these questions were answered,
the author then adapted the generic test cases to the
TPW
TM. This was a relatively short process compared
with what was needed to understand the regulation.
Expert and customer review
Once a good draft of the validation plan was together,
which included detailed step-by-step procedures for each
test case, the next step was to have it reviewed by an
outside expert. The author utilized a well-known phar-
maceutical industry consulting group. To help answer
Figure 1. TPW
TM Robotic Unit.
Figure 2. TPW
TM data architecture.
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the purpose of the regulation. The purpose can be
summarized as follows: (1) make sure that electronic
records and signatures are as credible as paper records
and signatures and (2) make sure the FDA can access the
information. This turned out to be good advice, because
the author found that it was much easier to interpret the
details when he kept that overall purpose in mind.
The experts also gave two pieces of advice for the test
plan. This ® rst was to give an overview of the product.
This should include what the instrument does and how
data are stored and manipulated. The idea is that when
someone reads the document for the ® rst time, they can
then easily relate between the regulation and the tests
performed on the product. The second suggestion was
that the test cases be organized in a more logical manner.
Originally the test cases were ordered to match that of
the sections from the requirement. This turned out to be
haphazard. The author changed the order to represent
how the user would approach the machine. First, they
would login, so the ® rst tests were for system security.
Next, they would con® gure the system, so the next tests
were for proper security-level checking. The changes
were made. It was now time for a review by Zymark’ s
customers.
Zymark’ s customers were very happy to give feedback on
the test plan. They were thrilled that Zymark was willing
to ask for it! One customer gave a really detailed critique
of the test cases. The customer let the author know that
he should not assume that the system would work a
certain wayÐ even if it were a function of the PC’ s
operating system. The customer said to make sure the
test was only against de® ned requirements. Another
suggestion was to record the test results using screen
captures. This was actually done for the TPW
TM V2.0
testing. From other suggestions, it was clear that they
wanted the tests to be very detailed. This was a direct
re¯ ection on what customers felt the FDA would like to
see.
Execution and results
Finally, it was time to run the validation. As is always the
case with a validation or testing project, preparation is
most of the work! The testing turned out to be very
useful. One non-compliance issue was discoveredÐ some
of the failed login attempts were not recorded to the audit
trail. It would record only the last failed attempt in a
series of tries. The testing also exposed some suggested
improvements. A suggested improvement is something
not required by the regulation but which is functionality
suggested by customers. Zymark’ s goal was to satisfy its
customers, so these suggestions were taken very seriously.
Another positive outcome of the exercise was good feed-
back on usability. By performing the testing, the author
discovered where improvements could be made on the
usability of the product.
The results showed that the product was not perfect.
Zymark used this information to create and release a
software patch that made the product 100% 21 CFR
Part 11 compliant.
Leveraging results from the project
A few months later, the author had the chance to test
another product for Part 11 compliance. This was for the
new product called Prelude
TM. Prelude
TM is the next
generation of Zymark’ s BenchMate
TM product. It is a
personal automation tool for the chemist. The question
was ` Can the validation work from the TPWII
TM be
leveraged for the Prelude
TM?’ A lot of time was put into
creating the generic plan for testing Part 11 compliance.
It was interesting to see if it paid oå for the second
product to be tested.
First review the Prelude
TM functionality and data archi-
tecture. The primary applications of the Prelude
TM
included a wide range of dilutions, standard preparation,
drug substance analysis, potency assays and solubility
testing. It can feed samples into a measuring device such
as an HPLC or UV, or it can store the sample using a
sample collection product call the EasyFill
TM.
Figure 3 shows the Prelude
TM Robotic Unit. The hard-
ware includes test tube racks, robotic arm, ® lter dispen-
ser, a dispense station which includes a four or ® ve-place
balance, and a barcode reader. Options that will become
available soon include a sonication station. The Archi-
tecture is identical to the TPW
TM (® gure 4). That made
creating the test procedures easy!
Figure 3. Prelude
TM Robotic Unit.
Figure 4. Prelude
TM data architecture.
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TM were perfect. It was 100%
compliant from the ® rst day of its life. By having a test
standard in place for Part 11 compliance, the product
was designed to meet the regulation. In this case, since
the product architecture was identical to the TPW
TM,
the test plan, procedures and results were designed,
documented and executed in less than a week. To give
more data behind the leveraging of the generic test plan,
the author is currently working on a test plan for an
upgrade to Zymark’ s MultiDose
1product. This product
has a diå erent architecture than the TPW
TM or the
Prelude
TM. It is estimated that the design of the test
plan/procedure will take about 3 weeks.
Summary
Zymark is now positioned to assure compliance for all its
productsÐ whether it be upgrading existing products or
creating new ones. The plan that was put together is a
roadmap that will be used. Zymark learned that the
regulation can be addressed with an isolated worksta-
tionÐ it was addressed successfully with the TPW
TM and
Prelude
TM. The value of customers input was incredible.
It is vital really to understand customers’ needs to meet
those needs. Finally, this exercise helped Zymark im-
prove the partnership it has with its customers. Zymark’ s
customers de® ne the quality of Zymark’ s products. Zy-
mark is now ready to meet their customers’ needs better.
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